SparX Therapeutics, Inc.

中国的科研软件正在走向全世界，鹰谷研发的化学结构编辑器InDraw，所绘制的化学结构式和反应式，已经被包括美国化学会、Elsevier等多家国际顶级出版社接收使用。 小鹰已挖掘到，在全球发表的近百篇国际SCI科技论文期刊中，InDraw被广泛使用。举例如下： 1. 在Journal of Medicinal Chemistry上发表的论文 Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure （在晶体结构指导下的微管蛋白和Src 激酶双靶点抑制剂的设计、合成及生物活性评估）. Lun Wang and et al. Journal of Medicinal Chemistry 2021, 64, 12, 8127-8141. 领域：药物化学。 Journal of Medicinal Chemistry是国际顶级药物化学期刊，影响因子8.0。 本文所有化合物2D结构由InDraw绘制。 图1.1：在文献关键图片中；化合物结构、局部区分标志（红色、虚线圈等）由InDraw绘制。 图1.2：文献方法部分；紫色矩形和黄色高亮InDraw处为使用场景描述——化合物绘制使用InDraw软件。 图1.3：InDraw绘制的化学结构和局部区分标志（红色、绿色、弧线）。 2. 在Computational and Structural Biotechnology Journal上发表的论文 ccTCM: A quantitative component and compound platform for promoting the research of traditional Chinese medicine （ccTCM:促进传统中药研究的定量成分和化合物平台）. Dongqing Yang and et al. Computational and Structural Biotechnology Journal,Volume 21,2023,Pages 5807-5817. 领域：中药、数据库、人工智能。 Computational and Structural Biotechnology，影响因子6.0，是国际AI制药权威期刊。 图2: 代表性中药（芦丁）的活性成分记录。左侧结构图由InDraw绘制，右侧分子式、分子量由InDraw计算。 3. 在Journal of Advanced Research上发表的论文 The link between deacetylation and hepatotoxicity induced by exposure to hexavalent chromium（去乙酰化与六价铬暴露引起的肝毒性之间的联系）. Qingyue Yang and et al. Journal of Advanced Research. 2021 Apr 8:35:129-140. 领域：生物学、毒理学。 Journal of Advanced Research是一份综合性研究期刊，影响因子11.4。 图3.1：文献方法部分；紫色矩形和黄色高亮InDraw处为使用场景描述——RES（Resveratrol，白藜芦醇）的3D结构下载于InDraw化合物数据库。 图3.2：RES（Resveratrol，白藜芦醇）的结构来自InDraw化合物数据库。 4. 在QSAR in Safety Evaluation and Risk Assessment上发表的论文 admetSAR—A valuable tool for assisting safety evaluation（admetSAR—辅助安全评估的宝贵工具）. Yaxin Gu and et al. QSAR in Safety Evaluation and Risk Assessment 2023, Pages 187-201. 领域：新药研发。 图4.1：admetSAR 2.0分析平台的架构和工作流。平台整合有InDraw编辑器及SMILES转换插件。 图4.2：文献方法部分；紫色矩形和黄色高亮InDraw处为使用场景描述——平台整合有InDraw编辑器及SMILES转换插件。 图4.3：InDraw编辑器在admetSAR 2.0的代表界面。 图4.4：admetSAR 2.0平台子模块ADMETopt可以帮助优化候选化合物的ADMET性质。4个代表性工作界面；其中也整合有InDraw编辑器组件。 5. 在Inorg. Chem. Front上发表的论文 Dual-targeting of the aromatase binding domain of heme and androstenedione by Pt(iv) prodrugs: a new treatment for postmenopausal breast cancer（铂IV前药对血红素和雄烯二酮芳香化酶结合域的双靶向作用：绝经后乳腺癌的新疗法）. Xiao-Meng Liu and et al.Inorg. Chem. Front., 2022,9, 3470-3483 领域：抗肿瘤药物。 图5.1：Aminoplatin-3分子的作用机制；其中化学结构、细胞膜、信号通路/流程、文字及背景色块修饰使用了InDraw软件。 图5.2：Aminoplatin等分子的合成策略（反应式），由InDraw绘制。 图5.3：InDraw绘制的结构式可以直接复制在核磁共振（NMR）分析软件中使用。 6. 在Science of the Total Environment上发表的论文 Enhancement of the degradation capacity of IsPETase for PET plastic degradation by protein engineering（通过蛋白质工程提高 IsPETase酶对聚对苯二甲酸乙二醇酯（PET）塑料的降解能力）. Yidi Liu and et al. Science of the Total Environment 834 (2022) 154947 领域：高分子/环保/酶和蛋白质工程 Science of the Total Environment是环境科学领域的顶尖期刊之一，影响因子8.2。 图6.1：可降解塑料新材料及蛋白质工程的核心概念图。InDraw被用于化学结构绘制。 图6.2：文献方法部分；紫色矩形和黄色高亮InDraw处为使用场景描述，其中3D结构绘制使用了InDraw附带的D3Pharma组件。 7. 在Food Chemistry上发表的论文 Synthesis, taste characteristics and taste mechanism of N-lactoyl leucine from soy sauce using sensory analysis and UPLC-MS/MS （利用感官分析和超高效液相色谱-质谱联用技术研究酱油中n -乳酰亮氨酸的合成、口感特征及口感机理）. Junwei Feng and et al. Food Chemistry. Volume 454, 1 October 2024, 139670 领域：食品。 Food Chemistry是食品领域的顶级期刊之一，影响因子8.5。 图7.1：文献方法部分；紫色矩形和黄色高亮InDraw处为使用场景描述——InDraw绘制了复杂的离子碎片（质谱有关）。 图7.2：InDraw绘制的质谱有关离子碎片示意图；电荷、楔形键、虚线等均可以按需要绘制，并且能以颜色区分。 8. 在Journal of Ethnopharmacology上发表的论文 Evaluation of analgesic and anti-inflammatory actions of indolealkylamines from toad venom in mice using lipidomics and molecular docking（用脂质组学和分子对接评价蟾蜍毒液中吲哚烷基胺对小鼠的镇痛和抗炎作用） Journal of Ethnopharmacology Dihui Xu and et al. 领域：生物学、药理学。 图8. Bufotenidine等结构由InDraw绘制。 总结： 在药化、药理、高分子、食品等领域，InDraw在企业界和学术界被广泛使用，支持绘制数千个结构式而不卡顿，可以进行结构式美化、理化性质计算，与微软或金山的Word/Excel/PPT通过Ctrl C/Ctrl V完美兼容，复制粘贴到Word/Excel/PPT后，生成高清的矢量图，并可双击进行重新编辑。还具备多种出版样式的选择，如ACS 1996、Adv. Synth. Catal. Document、I Draw Styles、J. Chin. Chem. Soc. Document、J. Het. Chem、J. Mol. Mod等。正因如此，InDraw结构式编辑器满足国际主流期刊的发表要求，不断被广大国内外科学家用于发表论文和专利。 InDraw的绝大部分功能均免费，满足几乎所有的化学相关研发办公和计算需求；企业版收费功能主要有：离线使用、InDraw for Exel（在Excel中：批量生成结构图、结构式搜索、打开和导出SDF文件、批量计算cLogP等）等功能，已被华为、艾力斯等公司采购使用，实现完全的国产替代。 关于鹰谷 让研发有数据、有智慧、有未来 上海鹰谷信息科技有限公司（Integle）成立于2013年，致力于为企业建立自己的研发数据库。以电子实验记录本为中心，提供电子实验记录本InELN、试剂与生物样本库存管理InWMS、科研采购管理InPMS、化合物与生物分子注册管理InCMS等数字化实验室软件，由科学家打造，拥有生物序列编辑器InSequence、结构式编辑器InDraw等工具类软件，经过10多年的迭代开发，掌握IUPAC中英文命名、化学结构高精度AI图像识别、质粒设计、引物设计等专业技术，实现国产替代，解决很多行业“卡脖子”问题。服务团队大多数为来自世界五百强、北京大学、复旦大学、上海交通大学、浙江大学等化学、生物领域的科学家和工程师，做到真正理解客户需求，为客户的业务场景提供更专业的解决方案，具备30分钟快速反馈的响应机制，让客户更安心。 目前已经服务了500 多家生物医药客户，其中包括80多家上市公司，率先出口美国，如华为、扬子江、倍特、马应龙、和记黄埔、艾力斯、人福医药、迈瑞医疗、晶泰、英矽智能、天境生物、益方生物、美国ADARx Pharmaceuticals、美国Staidson Biopharma、美国SparX Therapeutics、中科院上海神经科学研究所等企业或高校研究所。 鹰谷明星产品——电子实验记录本InELN，支持云端部署或本地私有部署，节省实验记录时间，确保记录完整准确，积累数据，提升管理效率。通过全文搜索、结构式搜索、基因序列比对、数据结构化等，便于合作者间实现网络协同、促进合作，大大提高团队工作效率，避免“一半人重复另一半人的失败”，成就“一半人复制另一半人的成功”，帮助企业50人做出100人的业绩，帮助企业采用新一代的数字化生产力工具和管理工具，在生物药物、小分子药物、医疗器械、新材料、化工、农业、食品等研发上抢占先机。 鹰谷核心工具软件——InDraw结构式编辑器，是国内首个自主研发的全功能化学结构式编辑器，旨在为化学和生物科研人员提供简单、易用的绘制化学结构式、反应式、高分子材料、生物聚合物、生物信号通路、科研素材的绘图工具，支持化学结构中文(全球首家)或英文的IUPAC命名，高精度AI化学结构式图像识别，HELM大分子分级编辑语言（用于绘制多肽、核酸、多糖、高分子材料等），兼容ChemDraw，有网页端、客户端两种版本，已被大量用于发表专利和论文，生成高质量的矢量图。 鹰谷新品工具软件——InSequence序列编辑器，对标SnapGene，由鹰谷纯自主研发，攻克分子生物学核心算法技术，可用于DNA/RNA/蛋白序列编辑，实现序列编辑器科研软件的国产替代，拥有自主知识产权，简单易用，免费下载。兼容GenBank、Addgene文件中的序列信息，支持自动标注与手动修改特征、酶切位点、引物、开放阅读框等信息，实时计算引物长度、Tm值、GC含量，高效设计引物，支持引物碱基的添加、删除与替换，支持自动翻译序列与翻译框架移动，快速分析特定的序列区域，支持收藏和管理多个序列、引物及酶组信息，支持与合作伙伴分享收藏夹内容，保持序列结构、引物、特征等信息的完整性和数据一致性，突破领域空白，持续升级迭代。 鹰谷新品工具软件——InPaper文献结构化系统，基于AI研发的专利/论文数据挖掘工具，旨在帮助化学、生物、材料等科学家们快速分析文献，实现从名称获取结构图，批量导出结构的SMILES/Mol文件，直接复制列表数据，组装构效关系等功能，还能跨多个文献进行全文搜索、结构式搜索，为大家建立一个可搜索的文献数据库。 //推荐阅读 如何使用InDraw画绚丽多彩的结构式 智能批量采集专利和期刊论文中的化学结构、生物活性和SAR数据，InPaper成功上线，限时免费试用！ 鹰谷信息，努力成为国际领先的实验室数智化供应商，让研发有数据、有智慧、有未来 对标SnapGene！再次攻克“卡脖子”技术！国内首款纯自主研发DNA/RNA/蛋白序列编辑器鹰谷InSequence正式发布！ 鹰谷喜报｜鹰谷信息入选2023年“专精特新”企业名单鹰谷InELN：携手国货药妆第一股贝泰妮子公司，助力多肽研发创新重磅！ 首创修复软骨损伤重组蛋白或将成为领域内First-in-Class！Nature Medicine发布！ 祝贺京新药业上线的鹰谷电子实验记录本成功通过第三方专业机构CSV验证 鹰谷InELN：助力宜昌人福药业数据合规建设，集成仪器物联网，实现数据自动汇交分析！ 合规案例 |和誉医药CSF-1R抑制剂Pimicotinib获美国FDA批准 硅谷滴血验癌创业公司实验造假致70亿投资款打水漂 鹰谷电子实验记录本InELN

CHICAGO, April 11, 2024 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has been successfully dosed with SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate, reaching a significant milestone in the fight against cancer. This innovative treatment, developed by SparX Group, is currently undergoing clinical trials at the HonorHealth Research Institute, with Dr. Justin Moser leading the study. Dr. Gui-Dong Zhu, Chief Executive Officer of SparX Group, expressed his enthusiasm: "The dosing of the first patient with SPX-303 at HonorHealth Research Institute is a crucial step forward in its clinical development process. We are honored to collaborate with Dr. Moser's team at the Research Institute to bring this innovative therapy into clinical trials. By fusing a best-in-class (BIC) nano-anti-PD-L1 with mAb-anti-LILRB2 epitopes, SPX-303 aims to unlock the full potentials in the immune system's ability to fight cancer. The trailblazing preclinical data of SPX-303 instilled confidence in us to harness its therapeutic prowess in clinical settings, particularly for patients who previously had limited treatment options." Dr. Justin Moser, associate clinical investigator at the Institute and clinical assistant professor at the University of Arizona College of Medicine-Phoenix, shared his optimism about the potential impact of SPX-303. "SPX-303 is designed to combat the myeloid cell-induced immunosuppression that often hinders the effectiveness of current cancer therapies. SPX-303's unique dual mechanism, targeting both myeloid cell and T-cell immune checkpoints, may offer a new avenue for enhancing the immune system's weaponry against cancer," said Dr. Moser. With the successful dosing of SPX-303, SparX Group is initiating three additional study sites for the ongoing Phase 1 clinical study. This study aims to evaluate SPX-303's safety, tolerability, and preliminary efficacy in patients with resistant or refractory solid tumors, potentially ushering in a new era of superior therapeutic solutions. SPX-303 stands as a first-in-its-class bispecific antibody therapy, ingeniously designed to simultaneously target two crucial immune checkpoint proteins, LILRB2 and PD-L1. These proteins play essential roles in maintaining immune balance and preventing autoimmune diseases. However, cancer cells often exploit these checkpoints as a defense against immune attacks. SPX-303 seeks to overcome this by enabling the immune system to recognize and destroy cancer cells effectively, representing a significant leap forward in cancer therapy. About SparX Biopharmaceutical: A research-driven, development-stage biopharmaceutical trailblazer, SparX Biopharmaceutical Corp. has a mission of "amplifying human immunity with groundbreaking antibody therapies." Through the utilization of big data analytics, including machine learning, SparX decrypts potential interactions within the vast complexity of biological information. With meticulous pharmacological analyses, backed by in vitro and in vivo evaluations using advanced mouse models, SparX is on a relentless quest to develop unparalleled therapeutics. SparX's robust target discovery platform, combined with the multifaceted SAILING™ antibody optimization system and groundbreaking bi-ADC technology, is poised to redefine the success metrics of empowered antibody drug development. Equipped with in-house cGMP facilities, SparX is on track to become a self-sustaining, fully integrated biopharmaceutical entity. For more information about the study, please visit and search for NCT06259552. About the HonorHealth Research Institute HonorHealth Research Institute is an international destination that is at the forefront of providing patients with a better quality of life through its clinical trials and innovative treatment options. Headquartered in Scottsdale, Arizona, the institute's team of physicians and researchers collaborate with experts from across the nation to offer life-changing therapies, drugs and devices. At HonorHealth Research Institute, patients have access to tomorrow's health innovations, today. Learn more at: HonorHealth.com/research. SOURCE SparX Group

CHICAGO, Oct. 30, 2023 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX Biopharmaceutical Corp. proudly announces that its Investigational New Drug (IND) application for SPX-303, a First-in-Class anti-LILRB2/PD-L1 bispecific antibody drug candidate, has been greenlighted by the U.S. Food and Drug Administration (FDA). This approval propels SparX's enduring commitment to deliver groundbreaking solutions to patients grappling with advanced or refractory solid tumors. Dr. Gui-Dong Zhu, Chief Executive Officer of SparX Biopharmaceutical, shared his exhilaration: "Receiving the FDA's green light on our IND application is a seminal moment in our ongoing journey to redefine the paradigms of cancer treatment. The preclinical data for SPX-303 not only showcases promise but facilitate out confidence to harness its therapeutic prowess in a clinical setting, particularly for patients who previously had limited treatment options." With this FDA endorsement, SparX Biopharmaceutical is primed to launch a Phase 1 clinical study, aiming to assess the safety, tolerability, and preliminary efficacy of SPX-303 in patients beleaguered by advanced or refractory solid tumors. This human trial is geared to evaluate the therapeutic potential of SPX-303, potentially heralding a new dawn of innovative and superior healthcare outcomes. Developed by SparX, SPX-303 is a First-in-Its Class bispecific antibody therapy, ingeniously engineered to engage two cardinal immune checkpoint proteins, LILRB2 and PD-L1, simultaneously. Acting as pivotal fulcrums in sustaining the immune system's equilibrium and vigor, these checkpoints help deter autoimmune anomalies. While LILRB2 majorly tempers overactive innate immune reactions, preserving the body's natural defense harmony, PD-L1—often overexpressed in tumor cells—judiciously modulates T cell activation, curating a precise immune response. Yet, cancers often manipulate these immune-checkpoints, equipping themselves with a defense mechanism against immune retaliation. SPX-303 is meticulously designed to dismantle this barrier, empowering the immune system to discern and fervently annihilate malignant cells, thereby charting a transformative trajectory in cancer therapy. About SparX Biopharmaceutical: A research-driven, development-stage biopharmaceutical trailblazer, SparX Biopharmaceutical Corp. has a mission of "amplifying human immunity with groundbreaking antibody therapies." Through the utilization of big data analytics, including machine learning, SparX decrypts potential interactions within the vast complexity of biological information. With meticulous pharmacological analyses, backed by in vitro and in vivo evaluations using advanced mouse models, SparX is on a relentless quest to develop unparalleled or superior therapeutics. SparX's robust target discovery platform, combined with the multifaceted SAILING™ antibody optimization system and groundbreaking bi-ADC technology, is poised to redefine the success metrics of empowered antibody drug development. Equipped with in-house cGMP facilities, SparX is on track to become a self-sustaining, fully integrated biopharmaceutical entity. SOURCE SparX Group